No Data
InnoCare Pharma Unveils 2023 Share Award Scheme
INNOCARE (09969.HK) spent 0.6906 million Hong Kong dollars to buy back 0.114 million shares on December 31.
Gelonghui, December 31丨INNOCARE (09969.HK) announced that on December 31, it spent 0.6906 million HKD to repurchase 0.114 million shares, with a repurchase price per share ranging from 5.94 to 6.12 HKD.
INNOCARE (09969.HK) repurchased 0.1 million shares at a cost of 0.599 million Hong Kong dollars on December 27.
Gelonghui, December 27, INNOCARE (09969.HK) announced that on December 27, it spent 0.599 million HKD to repurchase 0.1 million shares.
Kaiyuan Securities: Each subtype of hematological tumors has the potential to hatch "heavyweight bomb" drugs. Pay attention to Innovative Drugs companies.
The subtype of blood tumors is less aggressive with a longer treatment cycle, generally requiring long-term medication. Patients have relatively high viscosity and the potential for the emergence of "blockbuster" drugs.
INNOCARE (09969.HK) spent 0.6315 million HKD to repurchase 0.106 million shares on December 24.
Glory Hong Kong reported on December 24 that INNOCARE (09969.HK) announced that on December 24, 2024, it spent 0.6315 million Hong Kong dollars to repurchase 0.106 million shares, with the repurchase price ranging from 5.86 to 6 Hong Kong dollars per share.
InnoCare Pharma Granted Waiver for Director Appointment
No Data
